Enzychem Lifesciences Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Enzychem Lifesciences Corporation
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.
NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.
Takeda has linked up with COVID-19 vaccine frontrunner Novavax, while Daiichi Sankyo has been selected by Japan’s Ministry of Health, Labour and Welfare as an official participant under the first round of a national government initiative to build production capacity.
- Other Names / Subsidiaries
- Enzychem Lifesciences USA